載入中
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
前收盤價
US$7.43
+US$0.06 · +0.81%
盤中時間採用ET。市場資料可能有所延遲。
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
日內區間
目前US$7.43
52週區間
目前US$7.43
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
2
估值過高
情緒
43
多空交錯
風險
55
風險偏高
動能
37
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
日內區間
目前US$7.43
52週區間
目前US$7.43
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4826.6萬 EUR | 1.56億 EUR | 5399.7萬 EUR | 1.73億 EUR | 3476.3萬 EUR |
| 毛利 | 4826.6萬 EUR | 1.56億 EUR | 5399.7萬 EUR | 1.73億 EUR | 3476.3萬 EUR |
| 研究與開發 | 1.84億 EUR | 1.48億 EUR | 1.19億 EUR | 1.07億 EUR | 8757.4萬 EUR |
| 銷售、一般及管理費用 | 5118.4萬 EUR | 4644.9萬 EUR | 3819.8萬 EUR | 3612.4萬 EUR | 3380.8萬 EUR |
| 營業費用 | 2.3億 EUR | 1.94億 EUR | 1.56億 EUR | 1.43億 EUR | 1.21億 EUR |
| 利息收入 | 1717.9萬 EUR | 2500.1萬 EUR | 1384.5萬 EUR | 247.6萬 EUR | 13.3萬 EUR |
| 利息支出 | 94.6萬 EUR | 88.6萬 EUR | 83.1萬 EUR | 103.8萬 EUR | 56.6萬 EUR |
| 折舊和攤銷 | 1240萬 EUR | 1222.5萬 EUR | 723.4萬 EUR | 696.7萬 EUR | 526萬 EUR |
| 營業利益 | −1.82億 EUR | −3861.5萬 EUR | −1.02億 EUR | 2995.4萬 EUR | −8629.4萬 EUR |
| 淨利 | −1.96億 EUR | 1521.8萬 EUR | −9464.9萬 EUR | 2770.3萬 EUR | −9333.5萬 EUR |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.00
上漲空間 128.80%報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Developed World ex-US ETFSPDW144.41萬0.00%404.62億 USD0.03%US$49.98+0.64%
ALPS Medical Breakthroughs ETFSBIO141.2萬0.74%1.91億 USD0.50%US$55.04+2.03%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP132.87萬0.05%26.06億 USD0.20%US$66.35+1.13%
Tema Oncology ETFCANC107.96萬0.53%2.05億 USD0.99%US$40.7829+1.63%
Fidelity Nasdaq Composite Index ETFONEQ44.83萬—109.4億 USD0.21%US$107.81+0.63%
State Street SPDR S&P International Small Cap ETFGWX41.53萬0.05%9.08億 USD0.40%US$45.56+0.93%
Virtus Biotech Clinical Trials ETFBBC24.93萬0.61%4099.65萬 USD0.65%US$44.1456+2.08%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED24.3萬0.75%3296.48萬 USD0.44%US$33.8094+2.13%State Street SPDR Portfolio Developed World ex-US ETFSPDWALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P Kensho New Economies Composite ETFKOMPTema Oncology ETFCANCFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXVirtus Biotech Clinical Trials ETFBBCT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
